The results, published in Journal of Heart and Lung Transplantation, implanted the Jarvik 2015 Ventricular Assist Device in seven children ages 8 months to 7 years. The children spent months using the device before their transplant and were able to participate in normal play activities. All the children survived, though one child — whose heart recovered and thus did not require a transplant — had a stroke on the 53rd day following device implantation.
The device is not FDA approved.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
